The Claim
Apigenin does not reduce the number of senescent cells or the expression of senescence markers p16INK4a and p21CIP1 in vivo or in vitro, but it selectively suppresses the inflammatory components of the senescence-associated secretory phenotype (SASP), confirming its classification as a senomorphic rather than a senolytic agent.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Apigenin does not eliminate senescent cells or lower levels of p16INK4a and p21CIP1 proteins, but it reduces the release of inflammatory molecules from these cells, distinguishing it from agents that kill senescent cells.
See the scientific wording
Apigenin does not reduce the number of senescent cells or expression of senescence markers (p16INK4a, p21CIP1) in vivo or in vitro, but selectively suppresses the inflammatory SASP, confirming its classification as a senomorphic rather than senolytic agent.
Apigenin binds to a protein called PRDX6 and blocks its ability to release a fatty acid called arachidonic acid. This stops a chain of signals inside senescent cells that would normally turn on inflammatory messaging. Without this signal, the cells stop releasing harmful inflammatory chemicals, even though they remain senescent and keep their other aging markers.
What the research says
1 studyApigenin doesn’t kill old, damaged cells, but it stops them from sending out harmful inflammatory signals — like turning down the volume on their noisy behavior. This study shows that’s exactly what apigenin does in mice.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.